Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors.
Peptide-based vaccines aimed at the induction of effective T-cell responses against established tumors have not been successful in clinic and require the use of new adjuvants. One of those is a new adjuvant in which gangliosides are incorporated into the outer membrane protein complex of Neisseria meningitidis to form very small size proteoliposomes (VSSP). In a preclinical model of human papillomavirus HPV16-induced cervical cancer we show that vaccination with HPV 16 E7 derived minimal CTL peptide and VSSP protects mice against tumor challenge, induces regression of established tumors and produces E7-specific CD8+ T-cell responses.
Torréns
Isis
I
Department of Cancer, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana, Cuba.
Mendoza
Osmany
O
Batte
Aileen
A
Reyes
Osvaldo
O
Fernández
Luis E
LE
Mesa
Circe
C
Guillén
Gerardo
G
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D002460:Cell Line; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008807:Mice, Inbred BALB C; D027383:Papillomaviridae / Q000187:drug effects* / Q000276:immunology; D030361:Papillomavirus Infections / Q000276:immunology / Q000628:therapy*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology*; D011510:Proteolipids / Q000008:administration & dosage* / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D010446:Peptide Fragments; D011510:Proteolipids; D022223:Vaccines, Subunit; C020485:proteoliposomes